- Home
- / Sucampo Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sucampo Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$230.1 M
FY, 2016
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|
| Revenue | 54.8M | 81.5M | 89.6M | 115.5M | 153.2M | 230.1M |
| Revenue growth, % | 28.9% | 32.7% | 50.2% | |||
| Cost of goods sold | 3.0M | 12.4M | 16.3M | 36.7M | 76.0M | |
| Gross profit | 78.5M | 77.2M | 99.2M | 116.4M | 154.1M | |
| Gross profit margin, % | 96.3% | 86.2% | 85.9% | 76.0% | 67.0% | |
| General and administrative expense | 41.3M | 30.2M | 25.4M | 31.2M | 35.5M | 43.8M |
| Operating expense total | 83.6M | 70.1M | 68.0M | 72.0M | 72.0M | 100.2M |
| EBIT | (17.7M) | 8.3M | 9.2M | 27.2M | 44.5M | 53.9M |
| EBIT margin, % | -32.3% | 10.2% | 10.3% | 23.6% | 29.0% | 23.4% |
| Interest income | 249.0K | 179.0K | 124.0K | 172.0K | 181.0K | 72.0K |
| Interest expense | 2.5M | 2.3M | 1.2M | 98.0K | 784.0K | 39.5M |
| Pre tax profit | (21.9M) | 7.8M | 10.3M | 27.1M | 43.7M | 14.4M |
| Income tax expense | (4.6M) | 2.9M | 3.9M | 14.0M | 10.3M | (4.1M) |
| Net Income | (17.3M) | 4.8M | 6.4M | 13.1M | 33.4M | 18.5M |